Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer, March 2018

Free Subscription


Abstracts

Retrieve all available abstracts of the following 165 articles:
HTML format


 

Single Articles

  1. LEE MS, Lee J, Lee S, Yoo SM, et al
    Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer.
    Oncotarget. 2018;9:7961-7974.
    Abstract    

    Abstract available

  2. BAJAJ A, Martin B, Bhasin R, Hentz C, et al
    The Impact of Academic Facility Type and Case Volume on Survival in Patients Undergoing Curative Radiation Therapy for Muscle-Invasive Bladder Cancer.
    Int J Radiat Oncol Biol Phys. 2018;100:851-857.
    Abstract    

    Abstract available

  3. RICHARD PO, Ahmad AE, Bashir S, Zlotta A, et al
    Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A population-based analysis.
    Can Urol Assoc J. 2018 Feb 23. pii: cuaj.4870. doi: 10.5489/cuaj.4870.
    Abstract    

    Abstract available

  4. ZENG XT, Liu TZ, Gong K, He DL, et al
    The BPSC: A prospective study investigating the clinical effect of interventional therapy and the risk factors for bladder cancer and benign prostatic hyperplasia in Chinese population.
    J Evid Based Med. 2018;11:64-67.
    Abstract    

    Abstract available

  5. BOYUK A, Sanli O, Erdem S, Tefik T, et al
    The association between variant urothelial histologies, pathological stage and disease specific survival in patients with bladder cancer.
    Turk J Urol. 2018;44:24-30.
    Abstract    

    Abstract available

  6. YANG SL, Wang JJ, Chen M, Xu L, et al
    Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study.
    Int J Med Sci. 2018;15:228-237.
    Abstract    

    Abstract available

  7. BAGREZAEI F, Hassanshahi G, Mahmoodi M, Khanamani Falahati-Pour S, et al
    Expression of Inhibitor of Apoptosis Gene Family Members in Bladder Cancer Tissues and the 5637 Tumor Cell Line
    Asian Pac J Cancer Prev. 2018;19:529-532.
    Abstract    

    Abstract available

  8. MAYR R, Gierth M, Zeman F, Reiffen M, et al
    Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer.
    J Cachexia Sarcopenia Muscle. 2018 Feb 25. doi: 10.1002/jcsm.12279.
    Abstract    

    Abstract available

  9. SHAN G, Tang T, Qian H, Xia Y, et al
    Certain BCG-reactive responses are associated with bladder cancer prognosis.
    Cancer Immunol Immunother. 2018 Feb 24. pii: 10.1007/s00262-018-2127.
    Abstract    

    Abstract available

  10. MULDERS PFA, Martinez-Pineiro L, Heidenreich A, Babjuk M, et al
    Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial.
    Eur Urol Focus. 2018 Feb 21. pii: S2405-4569(18)30033.
    Abstract    

    Abstract available

  11. KRIEGMAIR MC, Wirtz RM, Worst TS, Breyer J, et al
    Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.
    Transl Oncol. 2018;11:467-476.
    Abstract    

    Abstract available

  12. TANG H, Shi W, Fu S, Wang T, et al
    Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.
    Cancer Med. 2018 Feb 24. doi: 10.1002/cam4.1354.
    Abstract    

    Abstract available

  13. NEAL DS
    Are You Developing an ABC: Advanced Bladder Cancer Clinic?
    Rev Urol. 2017;19:246-247.
    Abstract    



  14. CHENG ML, Iyer G
    Novel biomarkers in bladder cancer.
    Urol Oncol. 2018 Feb 19. pii: S1078-1439(18)30009.
    Abstract    

    Abstract available

  15. MITA K, Kobatake K, Ohara S, Kato M, et al
    [Clinical Benefits of Transurethral Resection Under Narrow Band Imaging for Non-Muscle Invasive Bladder Cancer].
    Hinyokika Kiyo. 2018;64:1-6.
    Abstract    

    Abstract available

  16. GROEBEN C, Koch R, Baunacke M, Schmid M, et al
    Urinary Diversion After Radical Cystectomy for Bladder Cancer: Comparing Trends in the US and Germany from 2006 to 2014.
    Ann Surg Oncol. 2018 Feb 21. pii: 10.1245/s10434-018-6381.
    Abstract    

    Abstract available

  17. MASUDA N, Ogawa O, Park M, Liu AY, et al
    Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer.
    Oncotarget. 2018;9:7101-7111.
    Abstract    

    Abstract available

  18. ZHANG X, Chen Y, Dong L, Shi B, et al
    Effect of selective inhibition of aquaporin 1 on chemotherapy sensitivity of J82 human bladder cancer cells.
    Oncol Lett. 2018;15:3864-3869.
    Abstract    

    Abstract available

  19. XU T, Du XW, Hu JB, Zhu YF, et al
    Anticancer effect of miR-96 inhibitor in bladder cancer cell lines.
    Oncol Lett. 2018;15:3814-3819.
    Abstract    

    Abstract available

  20. ZHU J, Huang Z, Zhang M, Wang W, et al
    HIF-1alpha promotes ZEB1 expression and EMT in a human bladder cancer lung metastasis animal model.
    Oncol Lett. 2018;15:3482-3489.
    Abstract    

    Abstract available

  21. BERNARD-TESSIER A, Bonnet C, Lavaud P, Gizzi M, et al
    [Atezolizumab (Tecentriq((R))): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma].
    Bull Cancer. 2018;105:140-145.
    Abstract    

    Abstract available

  22. YANG H, Wang N, Han S, Male M, et al
    Comparison of the efficacy and feasibility of laser enucleation of bladder tumor versus transurethral resection of bladder tumor: a meta-analysis.
    Lasers Med Sci. 2017;32:2005-2012.
    Abstract    

    Abstract available

  23. MOLLER KL, Brauer C, Mikkelsen S, Loft S, et al
    Copenhagen Airport Cohort: air pollution, manual baggage handling and health.
    BMJ Open. 2017;7:e012651.
    Abstract    

    Abstract available

  24. MIRZAEI MR, Mahmoodi M, Hassanshahi G, Ahmadi Z, et al
    Down-regulation of anti-apoptotic genes in tumor cell lines is facilitated by suppression of OCT4B1.
    Adv Med Sci. 2017;62:97-102.
    Abstract    

    Abstract available

  25. SONG W, Sung HH, Han DH, Jeong BC, et al
    The effect of contralateral kidney volume on renal function after radical nephroureterectomy: Implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer.
    Urol Oncol. 2017;35:114.
    Abstract    

    Abstract available

  26. LU DD, Boorjian SA, Raman JD
    Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists.
    Urol Oncol. 2017;35:113.
    Abstract    

    Abstract available

  27. TEOH JY, Chan ES, Yip SY, Tam HM, et al
    Comparison of Detrusor Muscle Sampling Rate in Monopolar and Bipolar Transurethral Resection of Bladder Tumor: A Randomized Trial.
    Ann Surg Oncol. 2017;24:1428-1434.
    Abstract    

    Abstract available

  28. PACKIAM VT, Agrawal VA, Cohen AJ, Pariser JJ, et al
    Lessons from 151 ureteral reimplantations for postcystectomy ureteroenteric strictures: A single-center experience over a decade.
    Urol Oncol. 2017;35:112.
    Abstract    

    Abstract available

  29. CHAPPIDI MR, Chalfin HJ, Johnson DJ, Kates M, et al
    Longer average blood storage duration is associated with increased risk of infection and overall morbidity following radical cystectomy.
    Urol Oncol. 2017;35:38.
    Abstract    

    Abstract available

  30. MYLONAS KS, O Malley P, Ziogas IA, El-Kabab L, et al
    Malignant urachal neoplasms: A population-based study and systematic review of literature.
    Urol Oncol. 2017;35:33.
    Abstract    

    Abstract available

  31. FROEHNER M, Koch R, Heberling U, Novotny V, et al
    An easily applicable single condition-based mortality index for patients undergoing radical prostatectomy or radical cystectomy.
    Urol Oncol. 2017;35:32.
    Abstract    

    Abstract available

  32. MAO SY, Xiong DB, Huang TB, Zheng JH, et al
    Expression of CUL1 correlates with tumour-grade and recurrence in urothelial carcinoma.
    ANZ J Surg. 2017;87.
    Abstract    

    Abstract available

  33. UNA OREJON R, Mateo Torres E, Huercio Martinez I, Jofre Escudero C, et al
    Application of ERAS (Enhanced Recovery After Surgery) and laparoscopic surgery in the management of patients with bladder cancer.
    Arch Esp Urol. 2018;71:178-186.
    Abstract    

    Abstract available

  34. ASANO T, Ohnishi K, Shiota T, Motoshima T, et al
    CD169-positive sinus macrophages in the lymph nodes determine bladder cancer prognosis.
    Cancer Sci. 2018 Mar 9. doi: 10.1111/cas.13565.
    Abstract    

    Abstract available

  35. MAYR R, Fritsche HM, Zeman F, Reiffen M, et al
    Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer.
    World J Urol. 2018 Mar 8. pii: 10.1007/s00345-018-2259.
    Abstract    

    Abstract available

  36. BAYNE CE, Farah D, Herbst KW, Hsieh MH, et al
    Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis.
    World J Urol. 2018 Mar 8. pii: 10.1007/s00345-018-2257.
    Abstract    

    Abstract available

  37. PIAO XM, Byun YJ, Kim WJ, Kim J, et al
    Unmasking molecular profiles of bladder cancer.
    Investig Clin Urol. 2018;59:72-82.
    Abstract    

    Abstract available

  38. EL-BABOULY IM, Desoky EAE, El Sayed D, Ali MM, et al
    The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette-Guerin response in nonmuscle invasive bladder cancer.
    Urol Oncol. 2018 Mar 5. pii: S1078-1439(18)30042.
    Abstract    

    Abstract available

  39. DONG L, Li Y, Xue D, Liu Y, et al
    PCMT1 is an unfavorable predictor and functions as an oncogene in bladder cancer.
    IUBMB Life. 2018 Mar 8. doi: 10.1002/iub.1717.
    Abstract    

    Abstract available

  40. ZENG XT, Liu XP, Liu TZ, Wang XH, et al
    The clinical significance of COL5A2 in patients with bladder cancer: A retrospective analysis of bladder cancer gene expression data.
    Medicine (Baltimore). 2018;97:e0091.
    Abstract    

    Abstract available

  41. UN S, Turk H, Dindar AS, Zorlu F, et al
    Does preoperative neutrophil/lymphocyte rate have an effect on survival of the bladder cancer patients who received radical cystectomy?
    J Cancer Res Ther. 2018;14:432-436.
    Abstract    

    Abstract available

  42. DU L, Duan W, Jiang X, Zhao L, et al
    Cell-free lncRNA expression signatures in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer.
    J Cell Mol Med. 2018 Mar 8. doi: 10.1111/jcmm.13578.
    Abstract    

    Abstract available

  43. SU Q, Tao T, Tang L, Deng J, et al
    Down-regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer.
    J Cell Mol Med. 2018 Mar 7. doi: 10.1111/jcmm.13571.
    Abstract    

    Abstract available

  44. ALTUNKOL A, Savas M, Dilmec F, Utangac MM, et al
    Detection of CYP1A1 and GSTP1 gene polymorphisms in bladder cancer patients in a Turkish population using a polymerase chain reaction-restriction fragment length polymorphism method.
    Turk J Urol. 2018;44:125-131.
    Abstract    

    Abstract available

  45. SEFIK E, Gunlusoy B, Aydogdu O, Topcu YK, et al
    Predictive role of neutrophil-to-lymphocyte ratio on upstaging of organ-confined invasive urothelial bladder cancer to non-organ-confined disease.
    Turk J Urol. 2018;44:119-124.
    Abstract    

    Abstract available

  46. YANG X, Shi Y, Yan J, Fan H, et al
    Downregulation of FoxM1 inhibits cell growth and migration and invasion in bladder cancer cells.
    Am J Transl Res. 2018;10:629-638.
    Abstract    

    Abstract available

  47. WU J, Wang J
    HMGN5 expression in bladder cancer tissue and its role on prognosis.
    Eur Rev Med Pharmacol Sci. 2018;22:970-975.
    Abstract    

    Abstract available

  48. THOMA C
    Bladder cancer: Mechanisms of anti-PDL1 resistance.
    Nat Rev Urol. 2018 Mar 6. pii: nrurol.2018.28. doi: 10.1038/nrurol.2018.
    Abstract    



  49. ESCORCIA FE, Steckler JM, Abdel-Atti D, Price EW, et al
    Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model.
    Mol Imaging Biol. 2018 Mar 5. pii: 10.1007/s11307-018-1177.
    Abstract    

    Abstract available

  50. KITTLER R, Shiang C, Hutchinson R, Kollipara RK, et al
    Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer.
    Oncotarget. 2018;9:9415-9424.
    Abstract    

    Abstract available

  51. D ANDREA D, Abufaraj M, Susani M, Ristl R, et al
    Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool.
    Urol Oncol. 2018 Mar 2. pii: S1078-1439(18)30040.
    Abstract    

    Abstract available

  52. VON LANDENBERG N, Aziz A, von Rundstedt FC, Dobruch J, et al
    Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer.
    Urol Oncol. 2018 Mar 2. pii: S1078-1439(18)30039.
    Abstract    

    Abstract available

  53. ZHANG Y, Li F, Yang F, Zeng WL, et al
    [Prognostic value of preoperative serum albumin in patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumor].
    Nan Fang Yi Ke Da Xue Xue Bao. 2018;38:192-197.
    Abstract    

    Abstract available

  54. SEABRA AB, Duran N
    Nitric oxide donors for prostate and bladder cancers: Current state and challenges.
    Eur J Pharmacol. 2018 Mar 1. pii: S0014-2999(18)30126.
    Abstract    

    Abstract available

  55. AQUILA L, Ohm J, Woloszynska-Read A
    The role of STAG2 in bladder cancer.
    Pharmacol Res. 2018 Mar 1. pii: S1043-6618(18)30004.
    Abstract    

    Abstract available

  56. XIE H, Zhan H, Gao Q, Jianfa Li, et al
    Synthetic artificial "long non-coding RNAs" targeting oncogenic microRNAs and transcriptional factors inhibit malignant phenotypes of bladder cancer cells.
    Cancer Lett. 2018 Mar 1. pii: S0304-3835(18)30179.
    Abstract    

    Abstract available

  57. CHEN S, Zhang N, Shao J, Wang X, et al
    Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials.
    Int J Surg. 2018;52:248-257.
    Abstract    

    Abstract available

  58. GRAMANN T, Schwab C, Zumstein V, Betschart P, et al
    Transurethral resection of bladder cancer on the lateral bladder wall without obturator nerve block: extent of adductor spasms using the monopolar versus bipolar technique-a prospective randomised study.
    World J Urol. 2018 Mar 1. pii: 10.1007/s00345-018-2248.
    Abstract    

    Abstract available

  59. CHEN J, Zhang H, Sun G, Zhang X, et al
    Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis.
    Int J Surg. 2018 Feb 26. pii: S1743-9191(18)30580.
    Abstract    

    Abstract available

  60. ZUIVERLOON TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, et al
    Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.
    Urol Oncol. 2018 Feb 26. pii: S1078-1439(18)30036.
    Abstract    

    Abstract available

  61. BOURLON MT, Velazquez HE, Luna-Santiago R, Vazquez-Manjarrez S, et al
    Is This Patient With Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment?
    Oncology (Williston Park). 2018;32:64-8.
    Abstract    



  62. CHAAYA G, Morales J, Castiglioni A, Subhani N, et al
    Paraganglioma of the Urinary Bladder: A Rare Cause of Hypertension and Urinary Tract Infections.
    Am J Med Sci. 2018;355:191-194.
    Abstract    

    Abstract available

  63. LIU C, Shui CL, Wang Q, Luo H, et al
    Mechanism of hif-1alpha mediated hypoxia-induced permeability changes in bladder endothelial cells.
    Braz J Med Biol Res. 2017;51:e6768.
    Abstract    

    Abstract available

  64. GLASS R, Rosen L, Chau K, Sheikh-Fayyaz S, et al
    Analysis of the Cytomorphological Features in Atypical Urine Specimens following Application of The Paris System for Reporting Urinary Cytology.
    Acta Cytol. 2018;62:54-61.
    Abstract    

    Abstract available

  65. RENSHAW AA, Gould EW
    High-Grade Urothelial Carcinoma on Urine Cytology Resembling Umbrella Cells.
    Acta Cytol. 2018;62:62-67.
    Abstract    

    Abstract available

  66. ALTOK M, Sahin AF, Gokce MI, Ekin GR, et al
    Ureteral orifice involvement by urothelial carcinoma: long term oncologic and functional outcomes.
    Int Braz J Urol. 2017;43:1052-1059.
    Abstract    

    Abstract available

  67. GWYNN ME, DeRemer DL
    The Emerging Role of PD-1/PD-L1-Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma.
    Ann Pharmacother. 2018;52:60-68.
    Abstract    

    Abstract available

  68. ZEQUI SC
    The Middle Term.
    Int Braz J Urol. 2017;43:577-578.
    Abstract    



  69. PAREKH A, Hagan I, Capaldi L, Lyburn I, et al
    Incidental Papillary Bladder Carcinoma on 18F-Fluoromethylcholine PET/CT Undertaken to Evaluate Prostate Malignancy.
    Clin Nucl Med. 2017 Jul 6. doi: 10.1097/RLU.0000000000001754.
    Abstract    

    Abstract available

  70. CHEN PY, Chiang PH
    Comparisons of Quality of Life and Functional and Oncological Outcomes after Orthotopic Neobladder Reconstruction: Prostate-Sparing Cystectomy versus Conventional Radical Cystoprostatectomy.
    Biomed Res Int. 2017;2017:1983428.
    Abstract    

    Abstract available

  71. MUTO S, Kitamura K, Ieda T, Shimizu F, et al
    A preliminary oncologic outcome and postoperative complications in patients undergoing robot-assisted radical cystectomy: Initial experience.
    Investig Clin Urol. 2017;58:171-178.
    Abstract    

    Abstract available

  72. MIN J, Geng H, Liu Z, Liang Z, et al
    ERK5 regulates tobacco smokeinduced urocystic epithelialmesenchymal transition in BALB/c mice.
    Mol Med Rep. 2017;15:3893-3897.
    Abstract    

    Abstract available

  73. MIAO C, Liang C, Zhu J, Xu A, et al
    Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis.
    Oncotarget. 2017;8:32309-32321.
    Abstract    

    Abstract available

  74. FIETKAU R
    [When is a nonsurgical approach possible for metastatic primary tumors and lymph node metastases of the urinary bladder and prostate?]
    Urologe A. 2017;56:570-578.
    Abstract    

    Abstract available

  75. BOTTKE D, Bolenz C, Ott S, Cebulla A, et al
    [When should the primary tumor of metastatic bladder or prostate cancer be treated using a nonsurgical regimen?]
    Urologe A. 2017;56:579-584.
    Abstract    

    Abstract available

  76. NIEDWOROK C, Rubben H
    [When is surgical treatment indicated in metastatic urothelial carcinoma and what is the scientific rationale?]
    Urologe A. 2017;56:585-590.
    Abstract    

    Abstract available

  77. ELLINGER J, Hauser S, Kubler H, Muller SC, et al
    [When is surgical resection of the primary tumor indicated in metastatic urothelial carcinoma of the bladder and what is the scientific rationale?]
    Urologe A. 2017;56:564-569.
    Abstract    

    Abstract available

  78. JUNG K, Ghatalia P, Litwin S, Horwitz EM, et al
    Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review.
    Clin Genitourin Cancer. 2017;15:e337-e343.
    Abstract    

    Abstract available

  79. ABDEL-RAHMAN O
    Squamous Cell Carcinoma of the Bladder: A SEER Database Analysis.
    Clin Genitourin Cancer. 2017;15:e463-e468.
    Abstract    

    Abstract available

  80. MARTINI T, Gilfrich C, Mayr R, Burger M, et al
    The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians.
    Clin Genitourin Cancer. 2017;15:356-362.
    Abstract    

    Abstract available

  81. SUNDARARAGHAVAN VL, Sindhwani P, Hinds TD Jr
    Glucuronidation and UGT isozymes in bladder: new targets for the treatment of uroepithelial carcinomas?
    Oncotarget. 2017;8:3640-3648.
    Abstract    

    Abstract available

  82. ILIJAZI D, Abufaraj M, Hassler MR, Ertl IE, et al
    Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer.
    Expert Rev Mol Diagn. 2018 Mar 15. doi: 10.1080/14737159.2018.1453808.
    Abstract    

    Abstract available

  83. HUANG J, Ma X, Zhang L, Jia H, et al
    Diagnostic accuracy of optical coherence tomography in bladder cancer patients: A systematic review and meta-analysis.
    Mol Clin Oncol. 2018;8:609-612.
    Abstract    

    Abstract available

  84. YOSHIDA T, Sopko NA, Kates M, Liu X, et al
    Three-dimensional organoid culture reveals involvement of Wnt/beta-catenin pathway in proliferation of bladder cancer cells.
    Oncotarget. 2018;9:11060-11070.
    Abstract    

    Abstract available

  85. FENG Z, Wang B
    Long non-coding RNA HNF1A-AS1 promotes cell viability and migration in human bladder cancer.
    Oncol Lett. 2018;15:4535-4540.
    Abstract    

    Abstract available

  86. SUGAWARA S, Yamada Y, Arai T, Okato A, et al
    Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: targeted genes are involved in bladder cancer pathogenesis.
    J Hum Genet. 2018 Mar 14. pii: 10.1038/s10038-018-0437.
    Abstract    

    Abstract available

  87. JORDAHL KM, Randolph TW, Song X, Sather CL, et al
    Genome-wide DNA methylation in pre-diagnostic blood and bladder cancer risk in the Women's Health Initiative.
    Cancer Epidemiol Biomarkers Prev. 2018 Mar 14. pii: 1055-9965.EPI-17-0951.
    Abstract    

    Abstract available

  88. JI D, Jiang L, Li Y
    MiR-192-5p suppresses the growth of bladder cancer cells via targeting Yin Yang 1.
    Hum Cell. 2018 Mar 13. pii: 10.1007/s13577-018-0201.
    Abstract    

    Abstract available

  89. STANIK M, Poprach A, Macik D, Capak I, et al
    Clinically node-positive bladder cancer: oncological results of induction chemotherapy and consolidative surgery.
    Neoplasma. 2018;65:287-291.
    Abstract    

    Abstract available

  90. KOLLARIK B, Zvarik M, Bujdak P, Weibl P, et al
    Urinary fluorescence analysis in diagnosis of bladder cancer.
    Neoplasma. 2018;65:234-241.
    Abstract    

    Abstract available

  91. TANG F, He Z, Lei H, Chen Y, et al
    Identification of differentially expressed genes and biological pathways in bladder cancer.
    Mol Med Rep. 2018 Mar 9. doi: 10.3892/mmr.2018.8711.
    Abstract    

    Abstract available

  92. WARLI SM, Kadar DD, Siregar GP
    Ki-67 Expression as a Predictive Factor of Muscle Invasion in Bladder Cancer.
    Open Access Maced J Med Sci. 2018;6:260-262.
    Abstract    

    Abstract available

  93. AZEVEDO R, Soares J, Peixoto A, Cotton S, et al
    Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology.
    Urol Oncol. 2018 Mar 9. pii: S1078-1439(18)30044.
    Abstract    

    Abstract available

  94. NIWA N, Kikuchi E, Matsumoto K, Kosaka T, et al
    Does switching the bacillus Calmette-Guerin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette-Guerin therapy?
    Urol Oncol. 2018 Mar 9. pii: S1078-1439(18)30045.
    Abstract    

    Abstract available

  95. TU H, Dinney CP, Ye Y, Grossman HB, et al
    Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study.
    Am J Clin Nutr. 2018;107:208-216.
    Abstract    

    Abstract available

  96. OOSTERLINCK W, Decaestecker K
    Update on early instillation of chemotherapy after transurethral resection of non-muscle-invasive bladder cancer.
    Expert Rev Anticancer Ther. 2018 Mar 15:1-7. doi: 10.1080/14737140.2018.1451748.
    Abstract    

    Abstract available

  97. NAZARI A, Khorramdelazad H, Hassanshahi G
    Correction to: Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
    Int J Clin Oncol. 2018 Mar 10. pii: 10.1007/s10147-018-1257.
    Abstract    

    Abstract available

  98. SANTI R, Cai T, Nobili S, Galli IC, et al
    Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study.
    Virchows Arch. 2018 Mar 10. pii: 10.1007/s00428-018-2310.
    Abstract    

    Abstract available

  99. JUE JS, Koru-Sengul T, Moore KJ, Miao F, et al
    Sociodemographic and survival disparities for histologic variants of bladder cancer.
    Can J Urol. 2018;25:9179-9185.
    Abstract    

    Abstract available

  100. MANACH Q, Cussenot O, Roupret M, Game X, et al
    Analysis of bladder cancer subtypes in neurogenic bladder tumors.
    Can J Urol. 2018;25:9161-9167.
    Abstract    

    Abstract available

  101. DA SILVA JNL, Ranzi AD, Carvalho CT, Scheide TV, et al
    Cell Cycle Markers in the Evaluation of Bladder Cancer.
    Pathol Oncol Res. 2018 Mar 9. pii: 10.1007/s12253-018-0389.
    Abstract    

    Abstract available

  102. SAINT-JACQUES N, Brown P, Nauta L, Boxall J, et al
    Estimating the risk of bladder and kidney cancer from exposure to low-levels of arsenic in drinking water, Nova Scotia, Canada.
    Environ Int. 2018;110:95-104.
    Abstract    

    Abstract available

  103. SHELMERDINE SC, Lorenzo AJ, Gupta AA, Chavhan GB, et al
    Pearls and Pitfalls in Diagnosing Pediatric Urinary Bladder Masses.
    Radiographics. 2017;37:1872-1891.
    Abstract    

    Abstract available

  104. MACGREGOR-RAMIASA M, McNicholas K, Ostrikov K, Li J, et al
    A platform for selective immuno-capture of cancer cells from urine.
    Biosens Bioelectron. 2017;96:373-380.
    Abstract    

    Abstract available

  105. MADEC FX, Hedhli O, Perrouin-Verbe MA, Levesque A, et al
    Feasibility, Morbidity, and Functional Results of Supratrigonal Cystectomy with Augmentation Ileocystoplasty by Combined Robot-Assisted Laparoscopy and Mini-Laparotomy Approach.
    J Endourol. 2017;31:655-660.
    Abstract    

    Abstract available

  106. PLANELLES GOMEZ J, Olmos Sanchez L, Cardosa Benet JJ, Martinez Lopez E, et al
    Holmium YAG Photocoagulation: Safe and Economical Alternative to Transurethral Resection in Small Nonmuscle-Invasive Bladder Tumors.
    J Endourol. 2017;31:674-678.
    Abstract    

    Abstract available

  107. DU E, Zhang C, Qin Z, Yang K, et al
    Low expression of TMEM67 is a critical predictor of poor prognosis in human urothelial carcinoma of the bladder.
    Urol Oncol. 2017;35:152.
    Abstract    

    Abstract available

  108. MOSCHINI M, Shariat SF, Abufaraj M, Soria F, et al
    The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes.
    Urol Oncol. 2017;35:151.
    Abstract    

    Abstract available

  109. VAN OSCH FHM, Jochems SHJ, Wesselius A, van Schooten FJ, et al
    A Stratified Meta-Analysis of the Association between Exposure to Environmental Tobacco Smoke during Childhood and Adulthood and Urothelial Bladder Cancer Risk.
    Int J Environ Res Public Health. 2018;15.
    Abstract    

    Abstract available

  110. DONG F, Shen Y, Xu T, Wang X, et al
    Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis.
    World J Surg Oncol. 2018;16:61.
    Abstract    

    Abstract available

  111. RASSY EE, Bakouny Z, Aoun F, Haddad FG, et al
    A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer.
    Immunotherapy. 2018 Mar 22. doi: 10.2217/imt-2017-0190.
    Abstract    

    Abstract available

  112. LEE J, McKinney KQ, Pavlopoulos AJ, Niu M, et al
    Altered Proteome of Extracellular Vesicles Derived from Bladder Cancer Patients Urine.
    Mol Cells. 2018 Mar 9. pii: molcells.2018.2110. doi: 10.14348/molcells.2018.2110
    Abstract    

    Abstract available

  113. XU R, Zhu X, Chen F, Huang C, et al
    LncRNA XIST/miR-200c regulates the stemness properties and tumourigenicity of human bladder cancer stem cell-like cells.
    Cancer Cell Int. 2018;18:41.
    Abstract    

    Abstract available

  114. ERDEM GU, Dogan M, Sakin A, Oruc Z, et al
    Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder.
    Oncol Res Treat. 2018;41.
    Abstract    



  115. CAI D, Liu Z, Kong G
    Molecular and Bioinformatics Analyses Identify 7 Circular RNAs Involved in Regulation of Oncogenic Transformation and Cell Proliferation in Human Bladder Cancer.
    Med Sci Monit. 2018;24:1654-1661.
    Abstract    

    Abstract available

  116. BESIROGLU H, Ozbek E
    Letter to the editor regarding the article "Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study".
    World J Urol. 2018 Mar 20. pii: 10.1007/s00345-018-2271.
    Abstract    



  117. KUKREJA JB, Shi Q, Chang CM, Seif MA, et al
    Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy.
    Surg Innov. 2018 Mar 1:1553350618764218. doi: 10.1177/1553350618764218.
    Abstract    

    Abstract available

  118. LUO KW, Lung WY, Chun-Xie, Luo XL, et al
    EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway.
    Oncotarget. 2018;9:12261-12272.
    Abstract    

    Abstract available

  119. LI B, Mao X, Wang H, Su G, et al
    Vasculogenic mimicry in bladder cancer and its association with the aberrant expression of ZEB1.
    Oncol Lett. 2018;15:5193-5200.
    Abstract    

    Abstract available

  120. NISHIYAMA N, Hotta H, Takahashi A, Yanase M, et al
    Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guerin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study.
    Urol Oncol. 2018 Mar 14. pii: S1078-1439(18)30065.
    Abstract    

    Abstract available

  121. HUANG X, Zhu H, Gao Z, Li J, et al
    Wnt7a activates canonical Wnt signaling, promotes bladder cancer cell invasion, and is suppressed by miR-370-3p.
    J Biol Chem. 2018 Mar 16. pii: RA118.001689. doi: 10.1074/jbc.RA118.001689.
    Abstract    

    Abstract available

  122. BLACK PC, Goebell PJ, Kamat AM, Nawroth R, et al
    Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series.
    Urol Oncol. 2018 Mar 13. pii: S1078-1439(17)30591.
    Abstract    



  123. KOUTROS S, Lenz P, Hewitt SM, Kida M, et al
    RE: Elevated Bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic.
    J Natl Cancer Inst. 2018 Mar 14. pii: 4935099. doi: 10.1093.
    Abstract    



  124. BONET M, Bonfill T, Nunez M, De Verdonces L, et al
    Correction to: Curative radiation therapy for very elderly bladder cancer patients with localized disease.
    Clin Transl Oncol. 2018 Mar 15. pii: 10.1007/s12094-018-1853.
    Abstract    

    Abstract available

  125. WANG C, Li A, Yang S, Qiao R, et al
    CXCL5 promotes mitomycin C resistance in non-muscle invasive bladder cancer by activating EMT and NF-kappaB pathway.
    Biochem Biophys Res Commun. 2018 Mar 16. pii: S0006-291X(18)30557.
    Abstract    

    Abstract available

  126. BILLIS A, Freitas LLL, Costa LBE, Barreto IS, et al
    Genitourinary Malignancies in Transplant or Dialysis Patients: The Frequency of Two Newly Described 2016 World Health Organization Histopathologic Types.
    Transplant Proc. 2017;49:1783-1785.
    Abstract    

    Abstract available

  127. MIYATA Y, Matsuo T, Nakamura Y, Yasuda T, et al
    Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
    Anticancer Res. 2018;38:1629-1635.
    Abstract    

    Abstract available

  128. MICHALSKA M, Schultze-Seemann S, Kuckuck I, Katzenwadel A, et al
    Impact of Methadone on Cisplatin Treatment of Bladder Cancer Cells.
    Anticancer Res. 2018;38:1369-1375.
    Abstract    

    Abstract available

  129. THALMANN GN
    Quality improvement in cystectomy care with enhanced recovery (QUICCER) study.
    BJU Int. 2017;119:4-5.
    Abstract    



  130. DASGUPTA P
    NICE guidance and the BJUI.
    BJU Int. 2017;120:743.
    Abstract    



  131. VAN HEMELRIJCK M
    Human development and its impact on genitourinary cancers.
    BJU Int. 2017;120:747-748.
    Abstract    



  132. MINERVINI A, Vanacore D, Vittori G, Milanesi M, et al
    Florence robotic intracorporeal neobladder (FloRIN): a new reconfiguration strategy developed following the IDEAL guidelines.
    BJU Int. 2018;121:313-317.
    Abstract    

    Abstract available

  133. STRATTON K
    Cystectomy for cT4 prostate cancer: the most radical treatment.
    BJU Int. 2017;120.
    Abstract    



  134. PERERA M, Papa N, Christidis D, McGrath S, et al
    The impact of the global bacille Calmette-Guerin shortage on treatment patterns: population-based data.
    BJU Int. 2018;121:169-172.
    Abstract    



  135. MOSSANEN M, Krasnow RE, Lipsitz SR, Preston MA, et al
    Associations of specific postoperative complications with costs after radical cystectomy.
    BJU Int. 2018;121:428-436.
    Abstract    

    Abstract available

  136. GUO RQ, Hong P, Xiong GY, Zhang L, et al
    Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis.
    BJU Int. 2018;121:184-193.
    Abstract    

    Abstract available

  137. CATTO JWF
    Speeding up recovery from radical cystectomy: how low can we go?
    BJU Int. 2017;120:162-163.
    Abstract    



  138. KOCH MO
    Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy.
    BJU Int. 2017;119:816.
    Abstract    



  139. VON LANDENBERG N, Speed JM, Trinh QD
    Do micropapillary patients benefit from chemotherapy?
    BJU Int. 2017;119:656-658.
    Abstract    



  140. DAVIS JW
    Biomarker classification, validation, and what to look for in 2017 and beyond.
    BJU Int. 2017;119:812-814.
    Abstract    



  141. SU J, Zhu Q, Yuan L, Zhang Y, et al
    Transumbilical laparoendoscopic single-site radical prostatectomy and cystectomy with the aid of a transurethral port: a feasibility study.
    BJU Int. 2018;121:111-118.
    Abstract    

    Abstract available

  142. FU H, Zhu Y, Wang Y, Liu Z, et al
    Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer.
    Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-2687.
    Abstract    

    Abstract available

  143. CHEVALIER MF, Bohner P, Pieraerts C, Lhermitte B, et al
    Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.
    Eur Urol. 2017;71:854-857.
    Abstract    

    Abstract available

  144. WANG L, Sustic T, Leite de Oliveira R, Lieftink C, et al
    A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Eur Urol. 2017;71:858-862.
    Abstract    

    Abstract available

  145. CUMBERBATCH MGK, Foerster B, Catto JWF, Kamat AM, et al
    Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review.
    Eur Urol. 2018 Mar 6. pii: S0302-2838(18)30121.
    Abstract    

    Abstract available

  146. DU P, Ye L, Yang Y, Jiang WG, et al
    [Corrigendum] Candidate of metastasis 1 regulates in vitro growth and invasion of bladder cancer cells.
    Int J Oncol. 2018 Feb 16. doi: 10.3892/ijo.2018.4277.
    Abstract    

    Abstract available

  147. LIU J, Zhai R, Zhao J, Kong F, et al
    Programmed cell death 4 overexpression enhances sensitivity to cisplatin via the JNK/c-Jun signaling pathway in bladder cancer.
    Int J Oncol. 2018 Mar 5. doi: 10.3892/ijo.2018.4303.
    Abstract    

    Abstract available

  148. OTTO W, van Rhijn BW, Breyer J, Bertz S, et al
    Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naive stage T1 high-grade urothelial bladder cancer.
    Int J Urol. 2018 Feb 22. doi: 10.1111/iju.13532.
    Abstract    

    Abstract available

  149. MIYAZAKI J, Onozawa M, Takaoka E, Yano I, et al
    Bacillus Calmette-Guerin strain differences as the basis for immunotherapies against bladder cancer.
    Int J Urol. 2018 Mar 5. doi: 10.1111/iju.13538.
    Abstract    

    Abstract available

  150. ZHANG J, Wang L, Mao S, Liu M, et al
    Transurethral en bloc resection with bipolar button electrode for non-muscle invasive bladder cancer.
    Int Urol Nephrol. 2018 Feb 24. pii: 10.1007/s11255-018-1830.
    Abstract    

    Abstract available

  151. UHLIG A, Amir Hosseini AS, Simon J, Lotz J, et al
    Gender-specific differences in disease-free, cancer-specific and overall survival after radical cystectomy for bladder cancer: a systematic review and meta-analysis.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39380-7. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  152. PERLIS N, Krahn MD, Boehme KE, Alibhai SM, et al
    The Bladder Utility Symptom Scale (BUSS): A Novel Patient-Reported Outcome Instrument in Bladder Cancer.
    J Urol. 2018 Mar 9. pii: S0022-5347(18)42498-6. doi: 10.1016/j.juro.2018.
    Abstract    

    Abstract available

  153. KAPADIA AA, Acevedo AM, Liu JJ, Garzotto M, et al
    Unconventional Bladder Preservation: Factors predicting Failure to Receive Definitive Surgery following Chemotherapy for Non-metastatic Muscle Invasive Bladder Cancer within the National Cancer Database.
    J Urol. 2018 Mar 15. pii: S0022-5347(18)42581-5. doi: 10.1016/j.juro.2018.
    Abstract    

    Abstract available

  154. SHEN P, Jing Y, Zhang R, Cai MC, et al
    Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.
    Oncogene. 2018 Mar 14. pii: 10.1038/s41388-018-0192.
    Abstract    

    Abstract available

  155. LIU S, Jiang H, Wen H, Ding Q, et al
    Knockdown of tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) enhances tumorigenesis both in vivo and in vitro in bladder cancer.
    Oncol Rep. 2018 Mar 5. doi: 10.3892/or.2018.6294.
    Abstract    

    Abstract available

  156. LIU X, Kong C, Zhang Z
    miR-130b promotes bladder cancer cell proliferation, migration and invasion by targeting VGLL4.
    Oncol Rep. 2018 Mar 6. doi: 10.3892/or.2018.6300.
    Abstract    

    Abstract available

  157. CERRUTO MA, D'Elia C, Siracusano S, Saleh O, et al
    Health-Related Quality of Life after Radical Cystectomy for Bladder Cancer in Elderly Patients with Ileal Orthotopic Neobladder or Ileal Conduit: Results from a Multicentre Cross-Sectional Study Using Validated Questionnaires.
    Urol Int. 2018 Mar 7. pii: 000487644. doi: 10.1159/000487644.
    Abstract    

    Abstract available

  158. DOGAN S, Hennig M, Frank T, Struck JP, et al
    Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice.
    Urol Int. 2018 Mar 6. pii: 000487405. doi: 10.1159/000487405.
    Abstract    

    Abstract available

  159. ASHRAFI-ASGARABAD A, Ayubi E, Sullman MJ, Safiri S, et al
    Re: Hussein et al.: Development and Validation of a Quality Assurance Score for Robot-assisted Radical Cystectomy: A 10-Year Analysis (Urology 2016;97:124-129).
    Urology. 2017;101:174.
    Abstract    



  160. GOROSPE L, Garcia-Santana E, Jane-Soler P, Gomez-Martinez MDV, et al
    Cardiac and Skeletal Muscle Metastases From Squamous Cell Carcinoma of the Bladder: Positron Emission Tomography-Computed Tomography Findings.
    Urology. 2017;100:e5-e6.
    Abstract    

    Abstract available

  161. RUBENWOLF PC, Hampel C, Roos F, Stein R, et al
    Continent Anal Urinary Diversion in Classic Bladder Exstrophy: 45-Year Experience.
    Urology. 2017;100:249-254.
    Abstract    

    Abstract available

  162. BREAM MJ, Maurice MJ, Altschuler J, Zhu H, et al
    Increased Use of Cystectomy in Patients 75 and Older: A Contemporary Analysis of Survival and Perioperative Outcomes From the National Cancer Database.
    Urology. 2017;100:72-78.
    Abstract    

    Abstract available

  163. GOLABESK T, Palou J, Rodriguez O, Parada R, et al
    Long-term Bladder and Upper Urinary Tract Follow-up Recurrence and Progression Rates of G1-2 Non-muscle-invasive Urothelial Carcinoma of the Bladder.
    Urology. 2017;100:145-150.
    Abstract    

    Abstract available

  164. SCHOMBURG JL, Krishna S, Cotter KJ, Soubra A, et al
    Preoperative Incidence of Deep Venous Thrombosis in Bladder Cancer Patients Undergoing Radical Cystectomy.
    Urology. 2018 Mar 15. pii: S0090-4295(18)30202.
    Abstract    

    Abstract available

  165. WYNER LM
    Leo Szilard's Bladder Cancer: Survival in the Nuclear Era.
    Urology. 2018 Mar 12. pii: S0090-4295(18)30178.
    Abstract    




Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;